These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 23207616)

  • 1. New developments in pancreatic cancer treatment.
    Krug S; Michl P
    Minerva Gastroenterol Dietol; 2012 Dec; 58(4):427-43. PubMed ID: 23207616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular therapy of pancreatic cancer.
    Plentz RR; Manns MP; Greten TF
    Minerva Endocrinol; 2010 Mar; 35(1):27-33. PubMed ID: 20386525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
    Herman JM; Fan KY; Wild AT; Hacker-Prietz A; Wood LD; Blackford AL; Ellsworth S; Zheng L; Le DT; De Jesus-Acosta A; Hidalgo M; Donehower RC; Schulick RD; Edil BH; Choti MA; Hruban RH; Pawlik TM; Cameron JL; Laheru DA; Wolfgang CL
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):678-85. PubMed ID: 23773391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Chemotherapy of pancreatic carcinoma].
    Lutz MP
    Praxis (Bern 1994); 2005 Jun; 94(22):933-5. PubMed ID: 15986638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging drugs in pancreatic cancer.
    Ducreux M; Boige V; Malka D
    Expert Opin Emerg Drugs; 2004 May; 9(1):73-89. PubMed ID: 15155137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
    Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
    BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chemotherapy of metastatic pancreatic adenocarcinoma: challenges and encouraging results].
    Conroy T; Mitry E
    Bull Cancer; 2011 Dec; 98(12):1439-46. PubMed ID: 22133915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer.
    Schirmer MA; Lüske CM; Roppel S; Schaudinn A; Zimmer C; Pflüger R; Haubrock M; Rapp J; Güngör C; Bockhorn M; Hackert T; Hank T; Strobel O; Werner J; Izbicki JR; Johnsen SA; Gaedcke J; Brockmöller J; Ghadimi BM
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26857392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.
    Ruess DA; Görgülü K; Wörmann SM; Algül H
    Drugs Aging; 2017 May; 34(5):331-357. PubMed ID: 28349415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohort.
    Maier-Stocker C; Bitzer M; Malek NP; Plentz RR
    Scand J Gastroenterol; 2014 Dec; 49(12):1480-5. PubMed ID: 25390691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastatic pancreatic cancer: old drugs, new paradigms.
    Conroy T; Gavoille C; Adenis A
    Curr Opin Oncol; 2011 Jul; 23(4):390-5. PubMed ID: 21505335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancreatic cancer: will incremental advances begin to make a difference?
    Holzman DC
    J Natl Cancer Inst; 2010 Dec; 102(24):1821-3. PubMed ID: 21139096
    [No Abstract]   [Full Text] [Related]  

  • 13. High EGFR mRNA expression is a prognostic factor for reduced survival in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
    Fujita H; Ohuchida K; Mizumoto K; Itaba S; Ito T; Nakata K; Yu J; Kayashima T; Hayashi A; Souzaki R; Tajiri T; Onimaru M; Manabe T; Ohtsuka T; Tanaka M
    Int J Oncol; 2011 Mar; 38(3):629-41. PubMed ID: 21243324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels.
    Du J; Gu J; Li J
    Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32677676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.
    Ellenrieder V; König A; Seufferlein T
    Digestion; 2016; 94(1):44-9. PubMed ID: 27438590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel discoveries targeting gemcitabine-based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination?
    Luo W; Yang G; Qiu J; Luan J; Zhang Y; You L; Feng M; Zhao F; Liu Y; Cao Z; Zheng L; Zhang T; Zhao Y
    Cancer Med; 2019 Oct; 8(14):6403-6413. PubMed ID: 31475468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies.
    Heinemann V; Reni M; Ychou M; Richel DJ; Macarulla T; Ducreux M
    Cancer Treat Rev; 2014 Feb; 40(1):118-28. PubMed ID: 23849556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer.
    Garrido-Laguna I; Uson M; Rajeshkumar NV; Tan AC; de Oliveira E; Karikari C; Villaroel MC; Salomon A; Taylor G; Sharma R; Hruban RH; Maitra A; Laheru D; Rubio-Viqueira B; Jimeno A; Hidalgo M
    Clin Cancer Res; 2011 Sep; 17(17):5793-800. PubMed ID: 21742805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics of long-term survivors of inoperable pancreatic cancer: an 8-year cohort analysis in Korea.
    Jo JH; Chung MJ; Park JY; Bang S; Park SW; Chung JB; Song SY
    Pancreas; 2014 Oct; 43(7):1022-31. PubMed ID: 24991970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy.
    Kim ST; Lim DH; Jang KT; Lim T; Lee J; Choi YL; Jang HL; Yi JH; Baek KK; Park SH; Park YS; Lim HY; Kang WK; Park JO
    Mol Cancer Ther; 2011 Oct; 10(10):1993-9. PubMed ID: 21862683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.